
April 15 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA THERAPEUTICS ANNOUNCES PIPELINE PROGRESS FOR MULTIPLE LIMB-GIRDLE MUSCULAR DYSTROPHY PROGRAMS
SAREPTA THERAPEUTICS INC: DATA EXPECTED FOR SRP-9003 FOR LGMD2E/R4 BY MID-2025
SAREPTA THERAPEUTICS INC: U.S. FDA HAS CONFIRMED THAT SCREENING AND DOSING MAY PROCEED IN STUDY SRP-9005-101 FOR LGMD2C/R5
SAREPTA THERAPEUTICS INC: ENROLLMENT AND DOSING COMPLETED IN STUDY SRP-9004-102 FOR LGMD2D/R3